Stem Cell Treatment for Ankylosing Spondylitis in Delhi, India

Causes

The exact cause of ankylosing spondylitis is not fully understood, but research points to a combination of genetic and immune-related factors:

Family History

AS tends to run in families. Patients with a first-degree relative who has the condition face a significantly higher likelihood of developing it themselves, pointing to a strong hereditary component.

The HLA-B27 Genetic Marker

HLA-B27 is a protein found on the surface of white blood cells that plays a role in how the immune system recognizes threats. Since the link was first identified in 1973, researchers have found that a large majority of AS patients — roughly 90% — carry this genetic marker. However, the relationship isn’t absolute: many people with HLA-B27 never develop AS, and a small percentage of AS patients test negative for it, suggesting other genetic and environmental factors are also involved.

Immune System Dysregulation

As with other autoimmune joint conditions, an overactive or misdirected immune response is believed to drive the chronic inflammation seen in AS, particularly at the entheses — the points where tendons and ligaments attach to bone. This is one reason researchers investigating regenerative therapies for AS are especially interested in the immunomodulatory properties of mesenchymal stem cells (see Mechanism), which are also being studied in related conditions such as Fibromyalgia and Osteoporosis.

Symptoms

Ankylosing spondylitis follows a highly individual course, and both severity and age of onset vary widely. Common symptoms include:

• Chronic pain and stiffness in the lower back and buttocks
• Pain that is typically worse in the morning or after periods of rest, and improves with movement or a warm shower
• Discomfort in tendons and ligaments (enthesitis)
• Reduced appetite
• Eye inflammation (uveitis)
• Persistent fatigue
• Peripheral joint pain — in the hips, knees, ankles, elbows, heels, or shoulders — particularly common in younger patients

Symptoms most often begin between ages 17 and 45, though the disease can appear in children or develop later in life. In the early stages, pain is usually dull, poorly localized, and may switch sides. A mild fever and general malaise can accompany the earliest flare-ups. Importantly, back pain from AS is inflammatory, not mechanical — meaning it doesn’t follow the typical pattern of pain that worsens with activity and improves with rest, which is how many other forms of back pain behave.

In some patients, especially younger ones, symptoms may first appear in a peripheral joint such as the heel or hip rather than the spine, which can make early diagnosis more difficult. Left unaddressed, ongoing inflammation can eventually restrict spinal mobility, so recognizing the pattern of symptoms early is valuable for pursuing timely diagnosis and management.

Diagnosis

There is no single definitive test for ankylosing spondylitis, and diagnosis is often delayed by several years because the condition frequently begins subtly in early adulthood. Physicians typically combine imaging, laboratory testing, and clinical history to reach a diagnosis:

Imaging

• X-rays of the spine and pelvis to detect structural changes, joint narrowing, or early fusion
• MRI, which can detect active inflammation in the sacroiliac joints and spine before it becomes visible on X-ray, allowing earlier detection

Blood Tests

Laboratory tests help confirm inflammatory activity and rule out other conditions. Blood work alone cannot diagnose AS, but combined with imaging and symptom history, it strengthens diagnostic confidence.

Reports We Typically Request

To evaluate a patient’s suitability for stem cell-based management, our medical team generally requests:

• HLA-B27 test
• X-ray of the spine and pelvis
• Complete blood test panel
• MRI of both hip joints, including the sacroiliac joints
• ESR (Erythrocyte Sedimentation Rate)
• C-reactive protein (CRP)
• 2D Echocardiogram

These reports, together with a full clinical history, allow our specialists to assess disease activity and determine whether a patient may be a candidate for the stem cell treatment protocol outlined below.

Treatment

Regenerative approaches to spondyloarthritis have advanced considerably in recent years. At Viezec, the stem cell treatment pathway for ankylosing spondylitis is built around adult mesenchymal stem cells (MSCs), most commonly sourced from umbilical cord (Wharton’s Jelly) tissue or bone marrow.

MSCs are studied for their dual regenerative and immunomodulatory properties. Rather than only easing symptoms, this investigational approach is being explored for its potential to help calm the inflammatory processes driving joint and spinal damage, while also supporting the repair of surrounding soft tissue through the release of growth factors and other signaling molecules.

The general treatment pathway includes:

1. Clinical Evaluation — A detailed review of imaging, lab results (see Diagnosis), and disease history to assess candidacy.
2. Source Selection — Determining whether autologous (the patient’s own) or allogeneic (donor-derived, HLA-matched) cells are the appropriate source.
3. Laboratory Processing — Cells are cultured and expanded in a certified, GMP-compliant laboratory under strict quality control (see Quality Certificate).
4. Implantation — Delivery of the processed cells using the method best suited to the patient’s disease pattern (see Implantation).
5. Monitoring and Follow-Up — Structured post-treatment assessments to track inflammatory markers and mobility over time.

This remains an investigational area of regenerative medicine, and it is generally positioned as a complement to — not a replacement for — conventional rheumatological care, including biologics and physiotherapy.

Implantation

Viezec works with hospitals in Delhi that offer several delivery methods for stem cell administration in ankylosing spondylitis, chosen based on the pattern and severity of a patient’s disease:

• Intravenous (IV) administration — systemic infusion into the bloodstream
• Intrathecal administration (lumbar puncture) — direct delivery into the spinal fluid, relevant where spinal inflammation is prominent
• Intramuscular injection — delivered into muscle tissue near affected areas
• Intra-arterial delivery — targeted delivery through an artery supplying the affected region
• Subcutaneous injection — administered just beneath the skin
• Liberation angioplasty — used in select cases involving vascular considerations
• Surgical administration — reserved for specific, more complex clinical scenarios

The choice and combination of delivery routes is determined by the treating specialist based on each patient’s imaging findings and disease pattern. For a more technical breakdown of how each method works, visit our page on Stem Cell Delivery Methods.

Improvements

Stem cell therapy for ankylosing spondylitis is explored as a way to reduce the burden of frequent doctor visits and ongoing symptom flare-ups that many AS patients experience. Based on patient-reported outcomes following treatment, commonly noted improvements include:

• A perceived slowing in the progression of spinal stiffness
• Reduced inflammation and joint pain
• Improved range of motion in the back and affected peripheral joints
• Less morning stiffness
• An overall improvement in day-to-day comfort and functional mobility

As with any regenerative therapy, individual results vary considerably depending on disease duration, severity, and each patient’s underlying biology. These improvements are reported outcomes, not guaranteed results — see the full Treatment Disclaimer below.

Mechanism

The stem cells used in our ankylosing spondylitis protocols are primarily mesenchymal stem cells derived from Wharton’s Jelly, the gelatinous connective tissue within the umbilical cord. Research suggests these cells may act on the specific inflammatory proteins associated with AS-related pain and joint damage, while also supporting the replacement of damaged tissue with new, healthy cellular material. MSCs are additionally studied for their potential role in wound repair and for forming a protective effect against secondary infection at the site of tissue damage.

At Viezec, patient safety is central to how sourcing decisions are made — wherever clinically appropriate, autologous (the patient’s own) cells are prioritized. The administration procedures used are minimally invasive and do not leave visible scarring. The broader objective of stem cell administration in this context is to help stimulate the body’s own regenerative and immune-regulating responses, rather than to introduce an external chemical agent.

To understand the underlying biological principles in more depth, visit our page on the Physiological Mechanism of Stem Cell Therapy.

Our Promise

Because ankylosing spondylitis is a lifelong condition, patients need consistent, transparent, and compassionate support — not just a single procedure. Our commitment to every AS patient includes:

• A dedicated team of specialists experienced in treating chronic inflammatory joint conditions
• Personalized care coordination for both domestic and international patients
• Transparency at every stage — from initial evaluation through to post-treatment follow-up
• Adherence to internationally recognized safety and quality protocols throughout sourcing, processing, and delivery
• Ongoing hospitality and logistical support so patients and their families can focus on recovery rather than arrangements

To understand why India has become a leading destination for regenerative medicine — covering cost, expertise, and infrastructure — visit Why Stem Cell Therapy in India.

Treatment Results

Mesenchymal stem cell use has been studied as a generally well-tolerated approach within regenerative medicine, valued for the cells’ capacity to differentiate into multiple tissue types and support the replacement of damaged cells with healthy ones. Past patients undergoing stem cell therapy for ankylosing spondylitis at our partner hospitals have reported outcomes including:

• Reduced inflammation and joint/spinal pain
• Decreased overall fatigue
• Improved appetite, with fewer digestive disruptions related to disease flare-ups

These are patient-reported outcomes from past cases and are shared for informational purposes; they do not represent a guarantee of results for any individual patient. For visual patient accounts, watch the videos on our YouTube channel.

Testimonials

Rohan S. – Mumbai, India – January 2020 – ⭐⭐⭐⭐☆
“Back pain from ankylosing spondylitis made daily life tough. After Viezec’s stem cell therapy, stiffness reduced, and I can sit and walk more easily.”

Emma L. – Manchester, UK – June 2020 – ⭐⭐⭐⭐⭐
“I had severe spinal stiffness for years. Post-treatment at Viezec, my flexibility improved, and pain has decreased significantly.”

Ahmed N. – Cairo, Egypt – November 2020 – ⭐⭐⭐⭐☆
“Ankylosing spondylitis caused constant discomfort. After stem cell therapy, I feel more mobile and energetic in my routine.”

Isabella R. – Rome, Italy – March 2021 – ⭐⭐⭐⭐⭐
“My posture was worsening due to AS. Viezec’s therapy gave me pain relief and better mobility, improving my confidence.”

George M. – Athens, Greece – September 2021 – ⭐⭐⭐⭐☆
“Before therapy, morning stiffness was unbearable. After treatment at Viezec, I wake up with less pain and more energy.”

Fatima A. – Dubai, UAE – February 2022 – ⭐⭐⭐⭐⭐
“Ankylosing spondylitis limited my daily activities. Stem cell therapy at Viezec reduced inflammation, and I feel active again.”

Daniel P. – Toronto, Canada – August 2022 – ⭐⭐⭐⭐☆
“I struggled with chronic pain and immobility. After Viezec’s therapy, my back pain reduced, and I regained flexibility.”

Sofia G. – Madrid, Spain – April 2023 – ⭐⭐⭐⭐⭐
“Living with AS was exhausting. Post stem cell therapy at Viezec, my joint pain eased, and I can move more freely.”

Oliver T. – Sydney, Australia – October 2023 – ⭐⭐⭐⭐☆
“My condition made even light exercise impossible. After treatment at Viezec, I can now stretch and walk comfortably.”

Hannah W. – Berlin, Germany – May 2025 – ⭐⭐⭐⭐⭐
“Stem cell therapy at Viezec transformed my daily life. My spinal stiffness reduced, and I finally feel more independent and mobile.”

Treatment Disclaimer

Before undergoing this procedure, patients should understand that stem cell therapy remains an experimental, investigational approach and may not produce the desired effect in every case. Depending on individual evaluation, treatment may be declined, or the proposed protocol may be adjusted based on the patient’s current health status.

Our priority is to provide the safest and most current techniques available, in line with internationally recognized standards. As with any medical treatment, no outcome can be guaranteed — every patient’s internal biology differs, and results vary from person to person even with a similar diagnosis. No embryonic or fetal stem cells are used in any of our treatment protocols.